共 50 条
- [41] Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical TrialTARGETED ONCOLOGY, 2019, 14 (05) : 541 - 550Mokdad, Ali A.Zhu, HaoBeg, Muhammad S.Arriaga, YullDowell, Jonathan E.Singal, Amit G.Yopp, Adam C.
- [42] Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical TrialTargeted Oncology, 2019, 14 : 541 - 550Ali A. MokdadHao ZhuMuhammad S. BegYull ArriagaJonathan E. DowellAmit G. SingalAdam C. Yopp
- [43] Treatment of basal cell carcinoma with intralesional interferon alfa-2b: an open-label clinical trialEXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (07) : 753 - 760Maleki, MasoudLayegh, PouranKiafar, BitaTeimoorian, MehrdadDarchini-Maragheh, EmadodinRazmara, Mahdi
- [44] A randomized phase II (RP2) trial of ridaforolimus (R) compared with progestin (P) or chemotheraphy (C) in female adult patients with advanced endometrial carcinoma.JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)Oza, A. M.Poveda, A.Clamp, A. R.Pignata, S.Scambia, G.Del Campo, J. M.McCormack, M.Sevcik, L.Schwartz, B. M.Guan, S.Lee, R.Cheng, J. D.Haluska, F. G.
- [45] Update on overall survival (OS) of RESCUE: An open-label, phase 2 trial of camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (HCC).JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Zhang, YunXu, JianmingShen, JieGu, ShanzhiWu, LihuaWu, JianShao, GuoliangZhang, YanqiaoXu, LiYin, TaoLiu, JingfengRen, ZhenggangXiong, JianpingMao, XianhaiZhang, LingYang, JiayinLi, LequnChen, XiaomingWang, ZhimingWang, Quanren
- [46] TORIPALIMAB IN COMBINATION WITH CONCURRENT CHEMORADIATION IN PATIENTS WITH ADVANCED/METASTATIC ESOPHAGEAL CARCINOMA: PROTOCOL FOR A SINGLE-ARM, PROSPECTIVE, OPEN-LABEL, PHASE II CLINICAL TRIALJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A444 - A444Wu, LeiWang, YiWan, GangLv, JiahuaWang, QifengLang, JinyiLi, Tao
- [47] Pemetrexed alone or in combination with cisplatin in the treatment of patients with advanced malignant mesothelioma: An open-label trial of the National Cancer Institute of EgyptLUNG CANCER, 2005, 49 : S220 - S221Gaafar, RSallam, YKhaled, HRizk, GEmara, MAbou El-Kasem, FEl-Din, NAAbou-Rabia, AHelal, MMokhtar, N
- [48] Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trialLANCET ONCOLOGY, 2015, 16 (15): : 1473 - 1482Motzer, Robert J.Hutson, Thomas E.Glen, HilaryMichaelson, M. DrorMolina, AnaEisen, TimothyJassem, JacekZolnierek, JakubPablo Maroto, JoseMellado, BegonaMelichar, BohuslavTomasek, JiriKremer, AltonKim, Han-JooWood, KarenDutcus, CorinaLarkin, James
- [49] A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular CarcinomaONCOLOGY, 2018, 94 (06) : 329 - 339Thomas, Melanie B.Garrett-Mayer, ElizabethAnis, MunazzaAnderton, KateBentz, TriciaEdwards, AndieBrisendine, AlanWeiss, GeoffreySiegel, Abby B.Bendell, JohannaBaron, AriDuddalwar, VinayEl-Khoueiry, Anthony
- [50] Open-label phase II trial of everolimus monotherapy in treatment-naive patients with advanced papillary renal cell carcinomaJOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Caglio, S.Slimane, K.May, C.Escudier, B.